StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Deutsche Bank Comments on Bristol-Myers Squibb (BMY) Opdivo News; Analyst Says Merck (MRK) Not Guaranteed to be Alone in Front-Line Setting
August 5, 2016 11:25 AM
Deutsche Bank analyst Gregg Gilbert commented on Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) following news BMY's Opdivo failed ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
August 8, 2016 6:37 AM
Credit Suisse Upgrades Merck (MRK) to Outperform
August 8, 2016 6:22 AM
Merck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial Fails
August 5, 2016 8:24 AM
Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
August 5, 2016 8:21 AM
Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
August 5, 2016 8:20 AM
